Structure Therapeutics American Stock Performance
| GPCR Stock | 34.20 0.44 1.30% |
The entity has a beta of 0.59, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Structure Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Structure Therapeutics is expected to be smaller as well. Structure Therapeutics has an expected return of -0.26%. Please make sure to validate Structure Therapeutics total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Structure Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Structure Therapeutics American has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in July 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 1.3 | Five Day Return (8.36) | Year To Date Return (15.33) | Ten Year Return 31.54 | All Time Return 31.54 |
1 | Disposition of 21997 shares by Fmr Llc of Structure Therapeutics subject to Rule 16b-3 | 03/14/2024 |
2 | Q1 2024 Earnings Forecast for Structure Therapeutics Inc. Issued By Leerink Partnrs - Defense World | 03/20/2024 |
3 | Stocks Rise Before the Open as Investors Shift Focus to Key U.S. Jobs Data, ECB Minutes on Tap - Barchart | 04/04/2024 |
4 | Cantor starts Structure at overweight, sees positive data for GLP-1 drug | 04/09/2024 |
5 | Analysts Set Structure Therapeutics Inc. Target Price at 85.71 - Defense World | 04/11/2024 |
6 | Insider Trading | 04/17/2024 |
7 | Structure Therapeutics Earns Overweight Rating from Cantor Fitzgerald - MarketBeat | 04/18/2024 |
8 | Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights | 05/09/2024 |
9 | Structure Therapeutics Earns Market Outperform Rating from JMP Securities - Defense World | 05/14/2024 |
10 | Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024 | 05/20/2024 |
11 | Franklin Resources Inc. Grows Holdings in Structure Therapeutics Inc. - Defense World | 05/28/2024 |
| Begin Period Cash Flow | 26.1 M |
Structure |
Structure Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,213 in Structure Therapeutics American on March 3, 2024 and sell it today you would lose (793.00) from holding Structure Therapeutics American or give up 18.82% of portfolio value over 90 days. Structure Therapeutics American is currently does not generate positive expected returns and assumes 3.7259% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Structure, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Structure Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Structure Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Structure Therapeutics American, and traders can use it to determine the average amount a Structure Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0705
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GPCR |
Estimated Market Risk
| 3.73 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Structure Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Structure Therapeutics by adding Structure Therapeutics to a well-diversified portfolio.
Structure Therapeutics Fundamentals Growth
Structure Stock prices reflect investors' perceptions of the future prospects and financial health of Structure Therapeutics, and Structure Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Structure Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 4.55 B | ||||
| Shares Outstanding | 46.62 M | ||||
| Price To Book | 4.04 X | ||||
| EBITDA | (101.74 M) | ||||
| Net Income | (89.54 M) | ||||
| Total Debt | 5.45 M | ||||
| Book Value Per Share | 9.76 X | ||||
| Cash Flow From Operations | (79.42 M) | ||||
| Earnings Per Share | (2.25) X | ||||
| Market Capitalization | 1.63 B | ||||
| Total Asset | 482.02 M | ||||
| Retained Earnings | (206.57 M) | ||||
| Working Capital | 448.87 M | ||||
About Structure Therapeutics Performance
To evaluate Structure Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Structure Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Structure Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Structure Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Structure's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.22) | (0.24) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.20) | (0.19) |
Things to note about Structure Therapeutics performance evaluation
Checking the ongoing alerts about Structure Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Structure Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Structure Therapeutics generated a negative expected return over the last 90 days | |
| Structure Therapeutics has high historical volatility and very poor performance | |
| Structure Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (89.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Structure Therapeutics generates negative cash flow from operations | |
| Structure Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Franklin Resources Inc. Grows Holdings in Structure Therapeutics Inc. - Defense World |
- Analyzing Structure Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Structure Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Structure Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Structure Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Structure Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Structure Therapeutics' stock. These opinions can provide insight into Structure Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Structure Therapeutics American. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Structure Therapeutics information on this page should be used as a complementary analysis to other Structure Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Structure Stock analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Structure Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Structure Therapeutics. If investors know Structure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Structure Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.25) | Return On Assets (0.22) | Return On Equity (0.33) |
The market value of Structure Therapeutics is measured differently than its book value, which is the value of Structure that is recorded on the company's balance sheet. Investors also form their own opinion of Structure Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Structure Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Structure Therapeutics' market value can be influenced by many factors that don't directly affect Structure Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Structure Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Structure Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Structure Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.